Targeting transmembrane TNF-α suppresses breast cancer growth

Cancer Research

Volumn 73, Issue 13, 2013, Pages 4061-4074

  Yu, Mingxia ^a,c   Zhou, Xiaoxi ^b   Niu, Lin ^a   Lin, Guohong ^a   Huang, Jin ^a   Zhou, Wenjing ^a   Gan, Hui ^a   Wang, Jing ^a   Jiang, Xiaodan ^a   Yin, Bingjiao ^a   Li, Zhuoya ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c WUHAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD44V6 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PLACEBO; TRANSMEMBRANE TUMOR NECROSIS FACTOR ALPHA MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER RESISTANCE; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; DRUG TARGETING; HUMAN; HUMAN CELL; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TUMOR REGRESSION;

ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MCF-7 CELLS; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; MICE, NUDE; SIGNAL TRANSDUCTION; TUMOR BURDEN; TUMOR NECROSIS FACTOR-ALPHA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84880049469     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-3946     Document Type: Article

References (37)

1. Li YC, Kong LH, Li KS. [Inducement effect of recombinant human TNFalpha on apoptosis of breast cancer cell line ZR75-1 and Its mechanism]. Ai Zheng 2006;25: 560-5.
2. Marr RA, Addison CL, Snider D, Muller WJ, Gauldie J, Graham FL. Tumour immunotherapy using an adenoviral vector expressing a membrane-bound mutant of murine TNF alpha. Gene Ther 1997;4: 1181-8.
3. Balkwill F. TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev 2006;25: 409-16.
4. Knight B, Yeoh GC, Husk KL, Ly T, Abraham LJ, Yu C, et al. Impaired preneoplastic changes and liver tumor formation in tumor necrosis factor receptor type 1 knockout mice. J Exp Med 2000;192: 1809-18.
5. Moore RJ, Owens DM, Stamp G, Arnott C, Burke F, East N, et al. Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med 1999;5: 828-31.
6. Orosz P, Echtenacher B, Falk W, Ruschoff J, Weber D, Mannel DN. Enhancement of experimental metastasis by tumor necrosis factor. J Exp Med 1993;177: 1391-8.
7. Malik ST, Naylor MS, East N, Oliff A, Balkwill FR. Cells secreting tumour necrosis factor show enhanced metastasis in nude mice. Eur J Cancer 1990;26: 1031-4.
8. Tisdale MJ. Cancer cachexia. Langenbecks Arch Surg 2004;389: 299-305.
9. Szlosarek PW, Balkwill FR. Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. Lancet Oncol 2003;4: 565-73.
10. Shi W, Li Z, Gong F. Comparison of the cytocidal effect induced by transmembrane and secreted TNF-alpha. Chin J Microbiol Immunol 1998;18: 499-504.
11. Yan D, Qin N, Zhang H, Liu T, Yu M, Jiang X, et al. Expression of TNFalpha leader sequence renders MCF-7 tumor cells resistant to the cytotoxicity of soluble TNF-alpha. Breast Cancer Res Treat 2009;116: 91-102.
12. Zhang H, Yan D, Shi X, Liang H, Pang Y, Qin N, et al. Transmembrane TNF-alpha mediates "forward" and "reverse" signaling, inducing cell death or survival via the NF-kappaB pathway in Raji Burkitt lymphoma cells. J Leukoc Biol 2008;84: 789-97.
13. Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol 2002;2: 364-71.
14. Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007;357: 228-38.
15. Brown ER, Charles KA, Hoare SA, Rye RL, Jodrell DI, Aird RE, et al. A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer. Ann Oncol 2008;19: 1340-6.
16. Harrison ML, Obermueller E, Maisey NR, Hoare S, Edmonds K, Li NF, et al. Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose. J Clin Oncol 2007;25: 4542-9.
17. Madhusudan S, Foster M, Muthuramalingam SR, Braybrooke JP, Wilner S, Kaur K, et al. A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer. Clin Cancer Res 2004;10: 6528-34.
18. Mitoma H, Horiuchi T, Tsukamoto H, Tamimoto Y, Kimoto Y, Uchino A, et al. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum 2008;58: 1248-57.
19. Sinnathamby G, Zerfass J, Hafner J, Block P, Nickens Z, Hobeika A, et al. ADAM metallopeptidase domain 17 (ADAM17) is naturally processed through major histocompatibility complex (MHC) class I molecules and is a potential immunotherapeutic target in breast, ovarian and prostate cancers. Clin Exp Immunol 2011;163: 324-32.
20. Beatty JD, Beatty BG, Vlahos WG. Measurement of monoclonal antibody affinity by non-competitive enzyme immunoassay. J Immunol Methods 1987;100: 173-9.
21. Friedmann E, Hauben E, Maylandt K, Schleeger S, Vreugde S, Lichtenthaler SF, et al. SPPL2a and SPPL2b promote intramembrane proteolysis of TNFalpha in activated dendritic cells to trigger IL-12 production. Nat Cell Biol 2006;8: 843-8.
22. Puig T, Aguilar H, Cufi S, Oliveras G, Turrado C, Ortega-Gutiérrez S, et al. A novel inhibitor of fatty acid synthase shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drugresistant cell lines. Breast Cancer Res 2011;13: R131.
23. Szlosarek P, Charles K, Balkwill F. Tumour necrosis factor-a as a tumour promoter. Eur J Cancer 2006;42: 745-50.
24. Domonkos A, Udvardy A, Laszlo L, Nagy T, Duda E. Receptor-like properties of the 26 kDa transmembrane form of TNF. Eur Cytokine Netw 2001;12: 411-9.
25. Li F, Sethi G. Targeting transcription factor NF-kappaB to overcome chemoresistance and radioresistance in cancer therapy. Biochim Biophys Acta 2010;1805: 167-80.
26. Eck MJ, Sprang SR. The structure of tumor necrosis factor-alpha at 2.6 A resolution. Implications for receptor binding. J Biol Chem 1989;264: 17595-605.
27. Meli M, D'Alessandro N, Tolomeo M, Rausa L, Notarbartolo M, Dusonchet L. NF-kappaB inhibition restores sensitivity to Fas-mediated apoptosis in lymphoma cell lines. Ann N Y Acad Sci 2003;1010: 232-6.
28. Deng LL, Shao YX, Lv HF, Deng HB, Lv FZ. Over-expressing CYLD augments antitumor activity of TRAIL by inhibiting the NFkappaB survival signaling in lung cancer cells. Neoplasma 2012; 59: 18-29.
29. Guo SY, Liu SG, Liu L, Zhou XJ, Gu Y. RNAi silencing of the MEKK3 gene promotes TRAIL-induced apoptosis in MCF-7 cells and suppresses the transcriptional activity of NF-kappaB. Oncol Rep 2012; 27: 441-6.
30. Hojilla CV, Jackson HW, Khokha R. TIMP3 regulates mammary epithelial apoptosis with immune cell recruitment through differential TNF dependence. PLoS ONE 2011;6: e26718.
31. Nabors LB, Suswam E, Huang Y, Yang X, Johnson MJ, King PH. Tumor necrosis factor alpha induces angiogenic factor up-regulation in malignant glioma cells: a role for RNA stabilization and HuR. Cancer Res 2003;63: 4181-7.
32. Shukla S, Gupta S. Suppression of constitutive and tumor necrosis factor alpha-induced nuclear factor (NF)-kappaB activation and induction of apoptosis by apigenin in human prostate carcinoma PC-3 cells: correlation with down-regulation of NF-kappaB-responsive genes. Clin Cancer Res 2004;10: 3169-78.
33. Hamaguchi T, Wakabayashi H, Matsumine A, Sudo A, Uchida A. TNF inhibitor suppresses bone metastasis in a breast cancer cell line. Biochem Biophys Res Commun 2011;407: 525-30.
34. Kulbe H, Hagemann T, Szlosarek PW, Balkwill FR, Wilson JL. The inflammatory cytokine tumor necrosis factor-alpha regulates chemokine receptor expression on ovarian cancer cells. Cancer Res 2005;65: 10355-62.
35. Sheen-Chen SM, Chen WJ, Eng HL, Chou FF. Serum concentration of tumor necrosis factor in patients with breast cancer. Breast Cancer Res Treat 1997;43: 211-5.
36. Afify A, McNiel MA, Braggin J, Bailey H, Paulino AF. Expression of CD44s, CD44v6, and hyaluronan across the spectrum of normalhyperplasia-carcinoma in breast. Appl Immunohistochem Mol Morphol 2008;16: 121-7.
37. Li J, Zha XM, Wang R, Li XD, Xu B, Xu YJ, et al. Regulation of CD44 expression by tumor necrosis factor-alpha and its potential role in breast cancer cell migration. Biomed Pharmacother 2012;66: 144-50.